BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
53.08
-1.77 (-3.23%)
Last updated: Nov 17, 2025, 10:42 AM CST

SHA:688166 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
23,18712,74814,7869,53515,05118,778
Upgrade
Market Cap Growth
70.33%-13.79%55.07%-36.65%-19.85%44.16%
Upgrade
Enterprise Value
25,00614,39115,98310,60615,56018,464
Upgrade
Last Close Price
54.8530.1534.8522.3636.1745.02
Upgrade
PE Ratio
373.5267.3973.0339.7961.70110.54
Upgrade
Forward PE
88.4728.0028.0028.0043.0652.05
Upgrade
PS Ratio
19.659.9412.549.3714.3023.91
Upgrade
PB Ratio
9.165.236.124.258.6413.11
Upgrade
P/TBV Ratio
9.835.546.524.549.4713.58
Upgrade
P/OCF Ratio
103.0951.9175.9230.6385.48120.81
Upgrade
EV/Sales Ratio
21.1911.2213.5510.4314.7923.51
Upgrade
EV/EBITDA Ratio
137.2948.5258.1139.1354.9286.56
Upgrade
EV/EBIT Ratio
-71.6876.7545.8462.45100.84
Upgrade
Debt / Equity Ratio
0.930.920.910.900.520.15
Upgrade
Debt / EBITDA Ratio
12.857.207.717.173.101.03
Upgrade
Asset Turnover
0.230.250.240.270.440.48
Upgrade
Inventory Turnover
1.621.581.741.632.332.14
Upgrade
Quick Ratio
0.811.061.491.921.232.39
Upgrade
Current Ratio
1.261.562.002.391.703.24
Upgrade
Return on Equity (ROE)
1.06%5.82%7.44%10.62%14.97%12.34%
Upgrade
Return on Assets (ROA)
0.62%2.46%2.69%3.79%6.49%7.04%
Upgrade
Return on Capital (ROIC)
0.67%2.70%2.93%4.19%7.25%7.72%
Upgrade
Return on Capital Employed (ROCE)
1.20%4.90%5.10%6.00%10.40%11.90%
Upgrade
Earnings Yield
0.27%1.48%1.37%2.51%1.62%0.91%
Upgrade
FCF Yield
-0.62%-0.09%-1.41%-4.36%-4.87%-1.06%
Upgrade
Dividend Yield
0.17%0.32%0.27%0.51%0.33%0.19%
Upgrade
Payout Ratio
176.87%71.75%56.80%41.77%22.26%20.84%
Upgrade
Buyback Yield / Dilution
0.21%0.34%-2.10%-1.61%1.87%-11.90%
Upgrade
Total Shareholder Return
0.39%0.66%-1.82%-1.10%2.21%-11.71%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.